D Ogoina1, G Onyemelukwe, B O Musa, A Babadoko. 1. Immunology unit, Department of Medicine, Ahmadu Bello University Teaching Hospital, Zaria. dimostic@yahoo.co.uk
Abstract
BACKGROUND: There is a dearth of studies on HHV8-HIV co-infections from Nigeria, even as both infections have been shown to be endemic in Africa. This study examined the seroprevalence and determinants of HHV8 infections in adult Nigerians with and without HIV-infection. METHODS: In 2007, a cross sectional study undertaken in a tertiary hospital in Zaria, northern Nigeria enrolled 71 HIV-1 positive adults without Kaposi's sarcoma and 85 apparently healthy HIV-negative adult volunteers of the general population. Anti-lytic antibodies to HHV8 infection was determined by ELISA. A univariate analysis including age, sex, marital status, past sexually transmitted disease (STD), past blood transfusion, HIV/AIDS staging and CD4 count was used to determine variables associated with HHV8 seropositivity. Significant variables were adjusted in a logistic regression model expressed in odds ratio (OR) with 95% confidence interval (CI). P<0.05 was considered significant RESULTS: The seroprevalence of HHV8 infection was 62% in HIV-1 positive patients and 25.9% in HIV negative adults (p<0.001). A past history of STD [OR= 2.88, 95% CI= 1.0 - 8.2] and advanced HIV/AIDS (WHO stage 3 and 4) [OR=3.5, 95% CI= 1.21-10.1] were the only variables independently associated with HHV8 seropositivity in HIV-infected patients. In HIV-negative adults, none of the variables was significantly associated with HHV8 seropositivity. CONCLUSION: The study findings suggest an adverse interaction between HHV8 and HIV-1. The higher prevalence of HHV8 infection in HIV-infected patients and its association with STD support a predominant sexual route of HHV8 transmission among adult Nigerians.
BACKGROUND: There is a dearth of studies on HHV8-HIV co-infections from Nigeria, even as both infections have been shown to be endemic in Africa. This study examined the seroprevalence and determinants of HHV8 infections in adult Nigerians with and without HIV-infection. METHODS: In 2007, a cross sectional study undertaken in a tertiary hospital in Zaria, northern Nigeria enrolled 71 HIV-1 positive adults without Kaposi's sarcoma and 85 apparently healthy HIV-negative adult volunteers of the general population. Anti-lytic antibodies to HHV8 infection was determined by ELISA. A univariate analysis including age, sex, marital status, past sexually transmitted disease (STD), past blood transfusion, HIV/AIDS staging and CD4 count was used to determine variables associated with HHV8 seropositivity. Significant variables were adjusted in a logistic regression model expressed in odds ratio (OR) with 95% confidence interval (CI). P<0.05 was considered significant RESULTS: The seroprevalence of HHV8 infection was 62% in HIV-1 positive patients and 25.9% in HIV negative adults (p<0.001). A past history of STD [OR= 2.88, 95% CI= 1.0 - 8.2] and advanced HIV/AIDS (WHO stage 3 and 4) [OR=3.5, 95% CI= 1.21-10.1] were the only variables independently associated with HHV8 seropositivity in HIV-infectedpatients. In HIV-negative adults, none of the variables was significantly associated with HHV8 seropositivity. CONCLUSION: The study findings suggest an adverse interaction between HHV8 and HIV-1. The higher prevalence of HHV8 infection in HIV-infectedpatients and its association with STD support a predominant sexual route of HHV8 transmission among adult Nigerians.
Authors: Wolfgang Hladik; Sheila C Dollard; Robert G Downing; Peter Kataaha; Philip E Pellett; John M Karon; Jonathan Mermin; Eve M Lackritz Journal: J Acquir Immune Defic Syndr Date: 2003-06-01 Impact factor: 3.731
Authors: Sam M Mbulaiteye; Ruth M Pfeiffer; Denise Whitby; Glen R Brubaker; John Shao; Robert J Biggar Journal: J Infect Dis Date: 2003-06-01 Impact factor: 5.226
Authors: Ulrich R Hengge; Thomas Ruzicka; Stephen K Tyring; Martin Stuschke; Michael Roggendorf; Robert A Schwartz; Siegfried Seeber Journal: Lancet Infect Dis Date: 2002-05 Impact factor: 25.071
Authors: Andrew A Adjei; Henry B Armah; Foster Gbagbo; Isaac Boamah; Clement Adu-Gyamfi; Isaac Asare Journal: BMC Infect Dis Date: 2008-08-18 Impact factor: 3.090
Authors: Sara Gianella; Sheldon R Morris; Christy Anderson; Celsa A Spina; Milenka V Vargas; Jason A Young; Douglas D Richman; Susan J Little; Davey M Smith Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: Dimie Ogoina; Reginald O Obiako; Haruna M Muktar; Mukhtar Adeiza; Aliyu Babadoko; Abdulaziz Hassan; Isa Bansi; Henry Iheonye; Matthew Iyanda; Eric Tabi-Ajayi Journal: AIDS Res Treat Date: 2012-09-17
Authors: Elizabeth M Etta; Doyinmola P Alayande; Lufuno G Mavhandu-Ramarumo; George Gachara; Pascal O Bessong Journal: Viruses Date: 2018-08-27 Impact factor: 5.048
Authors: Maxwell O Akanbi; Lucy A Bilaver; Chad Achenbach; Lisa R Hirschhorn; Adovich S Rivera; Olugbenga A Silas; Patricia A Agaba; Oche Agbaji; Nathan Y Shehu; Solomon A Sagay; Lifang Hou; Robert L Murphy Journal: Infect Agent Cancer Date: 2022-03-21 Impact factor: 2.965